Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss treatment Wegovy are among the 15 drugs targeted for ...

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...

Shares of Novo Nordisk (NYSE:NVO) fell 2% following the announcement of results from its STEP UP obesity trial, which showed ...

Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

When applying the treatment policy estimand 2, people treated with semaglutide 7.2 mg achieved a superior weight loss of 18.7% compared to a reduction of 15.6% with semaglutide 2.4 mg and 3.9% with ...

Novo Holdings plans to double its newly acquired contract drugmaker, Catalent, within five years, focusing on U.S. manufacturing. The $16.5 billion acquisition is aimed at enhancing supply chains amid ...

Danish business leaders, including Novo Nordisk's CEO, met with Prime Minister Mette Frederiksen to address potential ...

New data suggest Restylane Lyft or Contour in combination with Sculptra corrects contour deficiencies in patients ...

To get better results, labeling should be combined with industry-targeted measures like taxes and marketing restrictions, ...

Denmark’s Prime Minister Mette Frederiksen called business leaders to a meeting on Thursday after US President-elect Donald ...

WASHINGTON (Reuters) - Current laws and regulations are not enough to protect Americans from the risks of compounded versions ...